IFNA1 and myeloproliferative disorder: IFNα may have disease-modifying activity in MPNs as evidenced by preclinical studies; several small phase 2 studies have shown that IFNα treatment can induce molecular and cytogenetic responses in treated MPN patients, although the results vary according to the series.